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Abstract.
Background: There is insufficient available information on behavioral changes in the absence of cognitive impairment as
factors increasing the risk of conversion to dementia.
Objective: To observe and analyze patients with mild behavioral impairment (MBI), mild cognitive impairment (MCI), and
a psychiatry group (PG) to compare the risk of progression to dementia.
Methods: From 677 initially assessed ≥60-year-old patients, a series of 348 patients was studied for a five-year period until
censoring or conversion to dementia: 96 with MBI, 87 with MCI, and 165 with general psychiatry disorders, including 4
subgroups: Anxiety, Depression, Psychosis and Others. All patients were assessed with clinical, psychiatric, neurological,
neuropsychological, and neuroimaging studies.
Results: From 348 patients, 126 evolved to dementia (36.2%). Conversion was significantly higher in MBI (71.5%), followed
by the MCI-MBI overlap (59.6%) and MCI (37.8%) groups, compared to PG (13.9%) (Log-rank p < 0.001). MCI patients
mostly converted to Alzheimer’s dementia, while MBI converted to frontotemporal dementia and Lewy body dementia.
Patients in PG converted to Lewy body dementia and frontotemporal dementia.
Conclusion: Conversion to dementia is significantly higher in patients with neuropsychiatric symptoms. The MBI con-
cept generates a new milestone in the refining of diagnosis of neurodegenerative diseases and the possibility of creating
neuropsychiatric profiles. Its earlier identification will allow new possibilities for therapeutic intervention.
Keywords: Alzheimer’s disease, conversion to dementia, follow-up, frontotemporal disease, Lewy body disease, mild behav-
ioral impairment, mild cognitive impairment, pre-dementia
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INTRODUCTION
Even though it is known that neuropsychiatric
symptoms (NPS) are common in dementia and are
recognized as core to the dementia process by the
National Institute on Aging-Alzheimer’s Association
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(NIA-AA) [1], they still have not been extensively
studied in the pre-dementia stage. The NPS NIA-AA
core criteria for all-cause of dementia are described
as “changes in personality, behavior, or comport-
ment symptoms that include: uncharacteristic mood
fluctuations such as agitation, impaired motivation,
impaired initiative, apathy, loss of drive, social with-
drawal, decreased interest in previous activities,
loss of empathy, compulsive or obsessive behaviors,
social unacceptable behaviors” [1].
Instead, in mild cognitive impairment (MCI), those
NPS have been more characterized and the presence
of apathy, depression, agitation, delusions, hallucina-
tions, and sleep disorders has been associated with an
increased risk of progression to dementia [2, 3]. With
regards to dementia, NPS occur in 80–90% of patients
during the clinical course of the disease and fluctuate
over time. But, while these symptoms have been eval-
uated in cross-sectional studies, longitudinal studies
are scarce [4].
Since many years ago, there has been greater
awareness of the importance of NPS in dementia due
to their high prevalence, the increased caregivers’ bur-
den, and the early institutionalization of patients that
NPS induce [5–7]. Even more, it has been reported
that caregivers’ burden is more related to behavioral
disorders than to cognitive impairment [8, 9] and this
burden can be psychological and/or physical and/or
economic.
NPS are an important manifestation of the demen-
tia syndrome regardless of the underlying disease,
and have a strong correlation with the degree of
functional impairment. Taragano & Allegri (2003)
proposed the existence of a syndrome named ¨Mild
Behavioral Impairment” (MBI) [10]; at the Interna-
tional Conference of Alzheimer’s Disease (2004), it
was suggested that many patients convert to dementia
with NPS as the first indicators of the development
of a neurodegenerative disease [11]. Later (2008),
we published that MBI defines a late life syndrome
with prominent psychiatric and related behavioral
symptoms in the absence of major cognitive symp-
toms [12] and demonstrated (2009) that MBI is
associated with a greater and faster progression to
dementia [13].
Objective
The aim of our study was to observe and analyze
patients with MBI, MCI, and a psychiatric group to
compare the risk of progression to dementia.
MATERIALS AND METHODS
Study population
A 5-year prospective, longitudinal inception cohort
study was carried out with ≥60-year-old patients
attending to the Neuropsychiatry Research Unit of
CEMIC University Hospital between January 2007
and January 2012.
The neuropsychiatry research unit belongs to the
Neurology Section of the Medicine Department of
CEMIC University Hospital. The research group was
a multidisciplinary team composed by neurologists,
psychiatrists, gerontologists, neuropsychologists,
and psychologists. Patients were diagnosed with
MCI, MBI, or general psychiatry disorders.
Diagnosis
MBI was defined as a behavioral disturbance
not meeting NINCS-ADRDA [14] criteria for
Alzheimer’s dementia, Lund and Manchester cri-
teria [15] for frontotemporal dementia (FTD), and
DLB International Consortium criteria [16] for Lewy
body dementia (DLB). Additionally, patients must
not also meet the DSM-IV criteria [17] for psychosis
or another major psychiatric condition.
MBI inclusion criteria
a) Accept to participate in the study and signed
inform consent; b) Patients≥60 years old; c) Presence
of a major change in patient behavior this change
occurring later in life (≥60) that is persistent (≥6
months); d) No complaint of cognitive impairment by
patient/informant; e) Normal occupational and social
functioning; f) Normal activities of daily living; g)
Absence of dementia.
Major persistent changes in patient behavior that
might have led to a diagnosis of MBI are as follows:
agitation, anxiety symptoms, apathy, aspontaneity,
delusion symptoms, depressive symptoms, disin-
hibition, emotional lability, euphoria, impulsivity,
indifference, irritability, lack of empathy, loss of
insight, loss of personal hygiene, loss of social tact,
oral/dietary changes, perseverant behavior, sleep dis-
orders.
A patient with major persistent change in behavior
but no cognitive complaints from either the patient or
the caregiver was considered to have MBI regardless
of whether cognitive impairment was subsequently
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MBI exclusion criteria
a) Patients <60 years old; b) Impaired daily activ-
ities; c) Presence of Alzheimer’s dementia [14];
d) Presence of FTD [15]; e) Presence of LBD
[16]; f) Presence of another concomitant neurologi-
cal or psychiatric disorder that could better explain
disturbances (i.e., epilepsy, major stroke, tumors,
schizophrenia, etc.); g) Behavioral disturbances of
acute onset; h) Alcohol or substance abuse.
MCI was defined as a cognitive decline meeting
Petersen et al MCI criteria [18].
MCI inclusion criteria
a) Accept study participation and signed informed
consent; b) Age ≥60 years old; c) Memory complaint
or other cognitive complaint; d) Normal activities of
daily living; e) Normal general cognitive function;
f) Abnormal memory or other abnormal cognitive
functions for age; g) Not demented.
Abnormal memory or other abnormal cognitive
functions for age were defined as a score on a neu-
ropsychological standardized test 1.5 SD below the
mean compared with individuals of the same age and
level of education.
A patient with cognitive complaints and psy-
chiatric symptoms was considered to have MCI
regardless of whether NPS were subsequently found
on testing or not.
MCI exclusion criteria
a) Age <60 years old; b) Impaired daily activi-
ties; c) Presence of Alzheimer’s dementia [14]; d)
Presence of FTD [15]; e) Presence of LBD [16];
f) Presence of another concomitant neurological or
psychiatric disorder that could better explain the cog-
nitive symptoms (i.e., epilepsy, major stroke, tumors,
schizophrenia, etc.); g) Acute cognitive disturbances;
h) Alcohol or substance abuse.
The psychiatric group
In 2009, we demonstrated that MBI is associated
with a higher risk for dementia compared to MCI.
In the present study, we aim to verify if the risk of
conversion to dementia of the MBI group is different
from those patients with general psychiatric disorders
(PG).
Psychiatric illnesses were diagnosed according to
DSM-IV diagnostic criteria [17]. A complete semi
structured neuropsychiatric interview was performed
and neuropsychiatric general and focused scales were
used.
The following inclusion criteria were applied to
define the PG:
Inclusion criteria for the psychiatric group
Age ≥60 years old; Patients with general psychi-
atric disorders meeting DSM-IV diagnostic criteria
for major depression disorder (MDD), generalized
anxiety disorder (GAD), schizoaffective disorder
(SZD), personality disorder, post-traumatic stress
disorder (PTSD), bipolar disorder type I and II
(BPD I and BPD II); Patients without suspected or
reported dementia; If a patient had cognitive symp-
toms, a responsible family member or informant
should ensure that they were not the first symptoms
of the psychiatric illness.
Exclusion criteria for the psychiatric group
Age <60 years old; Impaired daily activities; Pres-
ence of Alzheimer’s dementia [14]; Presence of FTD
[15]; Presence of LBD [16]; Other neurological prob-
lem or psychiatric disorder that could better explain
the behavioral symptoms (e.g., epilepsy, tumors,
schizophrenia); Acute behavioral disturbances; Alco-
hol or substance abuse.
Screening procedure
All of the recruited patients signed a written
informed consent after they were given a full expla-
nation of the study. The research was performed
in accordance with the ICH Good Clinical Practice
guidelines, the latest revision of the 1964 Helsinki
Declaration (last amended in Seoul 2008), and the
Buenos Aires Government Health Authorities regu-
lations.
Patients were assessed using a semi-structured
neuropsychiatric interview and were examined at
least every 6 months or when necessary. At each visit
conversion to dementia was assessed.
Physical examinations and laboratory analysis
were performed at baseline and whenever was needed
as it is done in usual care.
Vascular risk factors and co-morbidities such as
body mass index >30, high blood pressure, high blood
cholesterol levels, cigarette smoking, diabetes, seden-
tary lifestyle, hypothyroidism and coronary heart
disease were assessed.
Two scales were used to assess psychiatric symp-
toms, the Beck Depression Scale [19] and The
Neuropsychiatric Inventory (NPI) [20].
An extensive neuropsychological battery to evalu-
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Mini-Mental State Examination (MMSE) [21], Digit
span [22], Trail making test “A&B” [23], Boston
naming test [24], Semantic and Verbal fluency [25],
Signoret memory battery [26], and Wechsler Scale of
Intelligence [27].
Methodology used to screen for conversion to
dementia
Clinical Dementia Rating Scale (CDR) was used
to evaluate the stage of cognitive impairment and
dementia [28, 29]. CDR from 0,5 to 1: When a sub-
ject convert from the CDR-0.5 score to CDR-1, it
was considered a significant clinical milestone in the
progression of the disease and was interpreted as the
conversion from mild deterioration stage to dementia
stage.
Structural imaging (Brain CT scan or MRI) was
performed at baseline to all participants for diagnostic
purpose.
Functional brain imaging (Tc99SPECT or
FDG18PET-CT) was performed only for research
purposes and it was planned to be obtained from at
least 30% of participants.
Statistical analysis
Variables from patients grouped within MBI, MCI,
and PG were compared. Categorical variables were
expressed as percentages. For continuous variables,
the mean and standard deviations were estimated. For
the non-normal distributed variables, the median and
percentiles were considered.
Differences in the frequency of distribution were
compared using univariate χ tests. Student’s t-
test was used to compare groups with continuous
variables, while non-parametric Mann-Whitney-
Wilcoxon and Kruskall-Wallis tests were used to
compare groups with non-normal distributed vari-
ables. Kaplan-Meier curves for survival analysis were
used to analyze the time from evolution to dementia.
The follow-up period for each patient was
from baseline visit to the evolution to dementia,
censoring or exclusion from the study. Mann-
Whitney-Wilcoxon U test and Cox proportional
models were also used to analyze associations
between multiple explanatory variables and conver-
sion to dementia. The effects are shown as risk indices
with 95% confidence interval. Stata 8.0 software was




Six hundred and seventy-seven ≥60-year-old
patients were initially assessed. Patients with pre-
existing dementia were excluded (n = 210), while
other 74 patients did not attend to follow up visits.
Patients with cognitive or behavioral symptoms not
attributable to a specific psychiatric disorder (n = 203)
were included: 87 MCI, 96 MBI, and 20 lost follow
up. The PG included 190 patients with specific psy-
chiatric disorders: 165 completed the study and 25
were lost in follow up.
Total study sample consisted of 348 patients.
Conformation of the psychiatric group
The PG was divided in four subtypes of psychi-
atric domains: Anxiety (GAD), n = 33; Depression
(MDD), n = 66; Psychosis (SZD), n = 31; and Oth-
ers (personality disorder, PTSD, BPD I, and BPD II),
n = 35.
Demographic data
Demographic data is depicted in Table 1. Con-
sidered variables showed no statistical differences
between groups.
Clinical characteristics
Family background of dementia
Statistical differences were found between MCI,
MBI, and PG groups (PG: χ2 = 19.0, df = 2, p < 0.001;
Table 2).
Neurological exam
The distribution of pyramidal, extrapyramidal
signs, and archaic reflexes was heterogeneous
(χ2 = 75.3, df = 6, p < 0.001) showing a greater fre-
quency of these symptoms in MBI patients (Table 2).
Psychopharmacological treatment
The prescription of psychopharmacological drugs
was heterogeneous between groups (χ2 = 42, df = 8,
p < 0.001), with the PG group showing the highest
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Table 1
Patients’ demographic characteristics at initial visit assessment
Variable MCI MBI Psychiatric group p value
n = 87 n = 96 n = 165 (%)
Age, mean (SD) 71.1 (7.7) 71.9 (8.9) 70.8 (7.5) p = 0.54∗
Gender
Female, n (%) 53 (61) 52 (55) 81 (51) χ2 = 3.23, df = 2, p = 0.199†
Civil status, n (%)
Married 57 (65.5) 67 (69.8) 112 (67.9) χ2 = 2.41, df = 6, p = 0.878†
Single 5 (5.7) 4 (4.2) 8 (4.8)
Divorced 5 (5.7) 8 (8.3) 16 (9.7)
Widowed 20 (23) 17 (17.7) 29 (17.6)
Years of education
Median 12.1 12 13.7 p = 0.229*
Under 9 years, n (%) 15 (17.2) 21 (21.8) 29 (17.6) χ2 = 0.896, df = 2, p = 0.639†
Job occupation, n (%)
Retired 70 (80.5) 74 (77.1) 115 (69.7) χ2 = 3.96, df = 2, p = 0.138†
Active 17 (19.5) 22 (22.9) 50 (30.3)
Months of follow up p < 0.001∗
Median 42 32 35
Percentile 10 13 11 11
Percentile 90 52 60 57
Number of visits p < 0.006∗
Median 7 10 6
Percentile 10 2 5 3
Percentile 90 21 23 12
∗Kruskal – Wallis test; †Pearson χ2.
Table 2
Clinical characteristics at initial visit assessment
Variable MCI MBI Psychiatric group p value
n = 87 (%) n = 96 (%) n = 165 (%)
Family background of dementia 16 (18.3) 25 (26) 11 (6.6) χ2 = 19.0, df = 2, p < 0.001∗
Neurological exam
Pyramidal signs 8 (9.1) 26 (21.8) 18 (11) χ2 = 75.3, df = 6, p < 0.001∗
Extrapyramidal signs 22 (9.2) 36 (37.5) 20 (12.1)
Archaic reflexes 10 (11.4) 45 (46.8) 28 (16.9)
Psychopharmacological treatment
Antidepressants 7 (8) 10 (10.4) 53 (32.2) χ2 = 42, df = 8, p < 0.001∗
Antipsychotics 5 (5.7) 20 (20.8) 31 (18.8)
Benzodiazepines 29 (33.3) 29 (30.2) 30 (18.1)
Others 10 (11.4) 21 (21.8) 25 (15.1)
∗Pearson χ2. Archaic reflexes were considered as PRESENT or ABSENT. PRESENT was defined when the patient had
one or more of the following reflexes: suck, snout, palmomental, and grasp reflexes, even though if they were found in a
mild presentation.
Vascular risk factors and co-morbidities
Significant differences were found between
groups in the following variables: BMI ≥30
(p = 0.046), coronary heart disease (p = 0.028), dia-
betes (p = 0.044), sedentary lifestyle (p = 0.001), and
dyslipidemia (p = 0.043). On the other hand, there
were no significant differences in number of co-
morbidities (p = 0.95). More detailed description
about these data is out of the scope of this paper.
Behavioral symptoms
Behavioral symptoms were found in almost a
quarter of MCI patients (Table 3). Irritability,
disinhibition, and delusions followed by nighttime
behaviors, depression, and apathy were the pre-
dominant symptoms in MBI group while anxiety,
irritability, and nighttime behaviors were the pre-
dominant symptoms in MCI group. No differences
between MCI and MBI groups were observed in
scores of Beck Depression Inventory.
Cognitive symptoms
Memory impairment symptoms were found in
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Table 3
Neuropsychiatric symptoms in MCI and MBI patients at initial assessment
MCI 87 MBI 96 p value
n (%) n (%)
Subjects with behavioral changes 21 (24.1) 96 (100) χ2 = 114, df = 1, p < 0.0001∗
assessed through NPI
Neuropsychiatric symptom:
Delusions 5 (5.7) 50 (52.0) χ2 = 46.6, df = 1, p < 0.0001†
Hallucinations 4 (4.5) 21 (21.8) χ2 = 11.6, df = 1, p < 0.001†
Agitation/Aggression 7 (8.0) 25 (26.0) χ2 = 10.2, df = 1, p < 0.001∗
Depression/Dysphoria 9 (10.3) 28 (29.1) χ2 = 10.0, df = 1, p < 0.002∗
Anxiety 19 (21.8) 39 (40.6) χ2 = 7.44, df = 1, p < 0.007∗
Elation/Euphoria 3 (3.4) 9 (9.3) χ2 = 5.39, df = 1, p < 0.020†
Apathy/Indifference 9 (10.3) 27 (28.1) χ2 = 5.97, df = 1, p < 0.015∗
Disinhibition 9 (10.3) 50 (52.0) χ2 = 24.7, df = 1, p < 0.001∗
Irritability/Lability 12 (13.7) 52 (54.1) χ2 = 31.4, df = 1, p < 0.001∗
Aberrant Motor Disturbance 5 (5.7) 24 (25.0) χ2 = 21.9, df = 1, p < 0.001†
Nighttime Behaviors 12 (13.7) 44 (45.8) χ2 = 22.1, df = 1, p < 0.001∗
Appetite/Eating 7 (8.0) 24 (25.0) χ2 = 14.6, df = 1, p < 0.001∗
Subjects with depressive symptoms
assessed through BDI
Mean (SD) 7.4(2.8) 8.9(2.4) z = 0.476 p = 0.565‡
Score ≥10 n (%) 7(8.0) 12 (12.5) χ2 = 0.973, df = 1, p = 0.32∗
∗Pearson χ2; †Fisherexact; ‡Wilcoxon Rank sum test; NPI, Neuropsychiatric Inventory; BDI, Beck Depres-
sion Inventory.
Table 4
Cognitive profile in MCI and MBI patients at initial assessment
MCI MBI p value
Total subjects in group, n (%) 87 (100) 96 (100)
Memory
Memory impairment, n (%) 87 (100) 26 (27.1) χ2 = 103, df = 1, p < 0.001∗
Immediate recall, median 7 6 z = –7.064 Prob> |z| = 0.000†
Delayed Recall, median 6 5 z = –3.781 Prob> |z| = 0.000†
Verbal serial learning, median 6 7 z = –5.099 Prob> |z| = 0.000†
Delayed serial memory, median 4 6 z = –5.305 Prob> |z| = 0.000†
Cued verbal recall, median 6 7 z = –1.607 Prob> |z| = 0.108†
Recognition, median 10 9 z = 2.790 Prob> |z| = 0.005†
Intrusions, n 30 45 χ2 = 2.9 df = 1, p = 0.089*
Total MMSE mean (SD) 27.9 (0.17) 26.9 (0.33) t = 4.420 P > |t| = 0.000‡
Naming
Boston Naming Test, mean (SD) 48.1 (0.44) 46.5 (0.55) t = 2.2663 P > |t| = 0.024‡
Fluency
Semantic fluency, median 14 15 z = 2.169 Prob>|z| = 0.030†
Phonological fluency, median 12 11 z = 0.433 Prob>|z| = 0.665†
Attention
Direct DigitSpan, median 7 6 z = 6.760 Prob>|z| = 0.000†
Reverse DigitSpan, median 5 5 z = 4.860 Prob>|z| = 0.601†
Sequencing
TrailMaking Test B, mean (SD) 114 (7.7) 165 (6.9) t = –2.616 P>|t| = 0.009‡
Intelligences
Vocabulary, median 53 47 z = –0.359 Prob>|z| = 0.719†
Analogies, median 47 38 z = –0.341 Prob>|z| = 0.519†
Block design, median 43 31 z = –4.309 Prob>|z| = 0.719†
Matrices, median 41 35 z = –3.508 Prob>|z| = 0.719†
Verbal IQ, mean (SD) 104.7 (1.3) 102.1 (1.1) t = 4.2665, p < 0.001‡
Performance IQ, mean(SD) 97.7 (1.5) 86.2 (1.2) t = 4.3675, p < 0.001‡
Global IQ, mean(SD) 101.2 (0.8) 94.1 (15.0) t = 6.2608, p < 0.001‡
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Table 5
Neuroimage findings in MCI and MBI patients
MRI and CT scan MCI MBI p value
n = 87 (%) n = 96 (%)
General atrophy 5 (5.7) 4 (4.2) χ2 = 2.44, df = 1, p = 0.621†
Leukoaraiosis 18 (20,6) 20 (20,8) χ2 = 0,57, df = 1, p = 0.981*
Focal atrophy 3 (3.4) 4 (4.2) χ2 = 0.640, df = 1, p = 0.800†
∗Pearson χ2; †Fisher Exact test.
Significant differences were observed in language;
verbal, executive and global IQ; attention; executive
functions; and total MMSE between MCI and MBI
groups (Table 4).
Neuroimaging findings
There were no significant differences (p > 0.05)
between MCI and MBI groups in patients with under-
ling vascular disease, atrophy (focal and general)
(Table 5).
Conversion to dementia
During the five-year follow-up period, from the
total 348 patients, more than a third part (36.2%,
n = 126) converted to dementia. A higher proportion
of the suspected pre-dementia patients (MBI plus
MCI) converted to dementia (56.3%, n = 103) with
a cumulative yearly rate of conversion of 10.0% for
the first year, 29.0% for the second year, 45.5% for
the third year, 50.0% for the fourth year, and 56.3%,
finally, for the fifth year. In terms of Kaplan-Meyer
analysis, as a result of the converted cases, the sur-
vival curve (free of dementia) was higher in the PG
(χ2 = 40.2, df = 3, p < 0.001; Fig. 1).
Frequency of conversion to dementia was: MBI
group 69.7% (n = 67); MCI group 41.3% (n = 36); and
PG 13.9% (n = 23).
Fig. 1. Kaplan-Meier estimate survival by diagnosis: psychiatric
group, mild cognitive impairment (MCI), and mild behavioral
impairment (MBI). Log-Rank test for the comparison of survival
curves upon time, adjusted by age: χ2 = 40.2, df = 3, p < 0.001.
According to different degenerative diseases, con-
version to dementia was: Alzheimer’s dementia
(NINCS-ADRDA criteria [14]): in MCI 83.3%
(n = 30), MBI 26.8% (n = 18), and PG 21.7% (n = 5);
FTD (Lund and Manchester criteria [15]): in MCI
16.6% (n = 6), MBI 44.7% (n = 30), and PG 30.4%
(n = 7); and DLB (DLB International Consortium cri-
teria [16]): in MCI 0%, MBI 28.3% (n = 19), and PG
47.8% (n = 11).
Frequency of conversion to different type of degen-
erative dementia in each studied group showed a
heterogeneous distribution between them (χ2 = 129,
df = 6 p < 0.001).
According to different subtypes of psychiatric
domains, conversion to dementia was: Anxiety 9.1%
(n = 3); Depression 15.2% (n = 10); Psychosis 25.8%
(n = 8); and Others 5.7% (n = 2)
Results showed that the distribution of cases that
converted to dementia was homogeneous among con-
sidered PG subgroups (p = 0.096).
Due to the frequency of NPS in MCI (24.1%), the
MCI group was divided in two subgroups: with and
without NPS. MCI with NPS symptoms group was
defined when at least 1 (one) or more NPS of any
domain were found in the NPI. Frequency of conver-
sion to dementia in MCI-with NPS was 52.4% while
in MCI-without NPS was 37.8% (Fig. 2).
Figure 2 displays Kaplan-Meier analysis adjusted
for age showing significant differences between all
survival curves as the result of conversion to dementia
cases.
Due to the frequency of cognitive symptoms
(CogS) found in MBI (27.1%), the MBI group was
divided in two subgroups: with and without CogS.
MBI with CogS were considered as patients pre-
senting cognitive impairment of more than 1.5 SD
in the neuropsychological tests performed after they
were included in MBI group. Frequency of conver-
sion to dementia in MBI-with CogS was 65.4% while
in MBI-without CogS was 71.5% (Fig. 3).
Assuming that MCI with NPS and MBI with
CogS could represent the same group or, at least,
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Fig. 2. Kaplan-Meier estimate survival by diagnosis: Psychiatric,
mild cognitive impairment (MCI) with and without neuropsychi-
atric symptoms (NPS), and mild behavioral impairment (MBI)
groups. Log-Rank test for the comparison of survival curves upon
time, adjusted by age: χ2 = 40.78, df = 3, p < 0.001.
Fig. 3. Kaplan-Meier estimate survival by diagnosis: psychiatric
group, mild cognitive impairment (MCI) with and without neu-
ropsychiatric symptoms (NPS), and mild behavioral impairment
(MBI) with and without cognitive symptoms (CogS). Log-Rank
test for the comparison of survival curves upon time, adjusted by
age: χ2 = 40.78, df = 3, p < 0.001.
Fig. 4. Kaplan-Meier estimate survival by diagnosis: psychi-
atric group, mild cognitive impairment (MCI), MCI-MBI overlap
group, and mild behavioral impairment (MBI). Log-Rank test for
the comparison of survival curves upon time, adjusted by age:
χ2 = 40.78, df = 3, p < 0.001.
patients in the following way: MCI, overlapping
group (MCI-MBI), MBI, and PG. In this new anal-
ysis, we gathered both MCI patients with NPS and
MBI patients with cognitive objective impairment:
this new group is defined as the MCI-MBI overlap
group (Fig. 4).
Initial diagnosis and conversion to different types
of dementia is depicted in Table 6.
DISCUSSION
It has long been recognized that behavioral symp-
toms might be an early manifestation of dementia.
In 2003, the International Statistical Classification of
Diseases and Related Health Problems (WHO) stated
“ . . . the impairments of cognitive function are com-
monly accompanied and occasionally preceded by
deterioration in emotional control, social behavior,
or motivation . . . [30]”.
Since then we have been investigating behavioral
changes in elderly patients and their relationship with
the development of different types of dementia and,
within this context, the concept of MBI was devel-
oped as a potential pre-dementia construct.
Identifying an MBI population is a novel approach
to study prevention strategies, with the hypothesis
that early identification and treatment of behavioral
symptoms in neurodegenerative illness could slow
or mitigate the presentation of psychiatric complica-
tions of dementia. Moreover, the MBI concept may
allow current medication or future disease modify-
ing agents to be used earlier in the course of the
disease. However, since there is an increased inter-
national interest in the MBI concept, as suggested by
other authors, it is necessary to be aware of the poten-
tial increase of over-diagnosis because of the current
lack of evidence showing specific advantages from
identifying and targeting MBI [31].
In early 2016, the Alzheimer’s Association Inter-
national Society to Advance Alzheimer’s Research
and Treatment (ISTAART) stated that it was nec-
essary to develop a specifically designed scale for
MBI to accurately estimate prevalence and as a
later outcome, allow the measurement of preventive
therapies [32].
Therefore, ISTAART made explicit the definition
of MBI and its differences with MCI. Firstly, the
ISTAART MBI criteria requires changes in behav-
ior or personality observed by patient, informant, or
clinician, starting later in life (age ≥50 years) and
persisting at least intermittently for ≥6 months. Sec-
ondly, behaviors are of sufficient severity to produce
at least minimal impairment. Thirdly, the impairment
in social, occupational, or interpersonal function must
be attributable to NPS such as changes in personality
and behavior, and not to cognitive decline. Finally,
if MBI is diagnosed concurrently with MCI, the
functional impairment must be attributed to behav-
ior or personality changes, and not the cognitive
impairments, although this may be difficult to ascer-
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Table 6
Initial diagnosis and conversion to different types of dementia
Initial Diagnosis
Psychiatric illnesses subgroups
Type of MBI MCI Depression Psychosis Anxiety Other Total
dementia, n (%) n = 96 n = 87 n = 66 n = 31 n = 33 n = 35 n = 348
Alzheimer’s 18 (18.75) 30 (34.48) 4 (6.06) 2 (6.45) 1 (3.03) 1 (2.85) 56 (44.4)
Frontotemporal 30 (31.25) 6 (6.89) 2 (3.03) 3 (9.67) 1 (3.03) 0 (0.00) 42 (33.3)
Lewy body 19 (19.79) 0 (0.00) 4 (6.06) 3 (9.67) 1 (3.03) 1 (2.85) 28 (22.2)
Total n (%) 67 (53.2) 36 (28.6) 10 (7.9) 8 (6.3) 3 (2.4) 2 (1.6) 126 (36.20)
Pearson χ2 = 132, df = 15, p < 0.0001.
use of the NIA-AA consensus criteria for MCI and
dementia.
Later, the ISTAART expanded on the description
of behavioral changes dividing them into five sub-
categories: motivation, affect, impulse control, social
appropriateness, and perception/thought content.
MBI subcategories may be correlated with NPI symp-
toms as follow: decreased motivation (NPI: apathy/
indifference); affective dysregulation (NPI: depres-
sion/dysphoria, anxiety, elation/euphoria, and irritab-
ility); impulse dyscontrol (NPI: agitation/aggression,
aberrant motor behavior, and appetite/eating behav-
ior); social inappropriateness (NPI: disinhibition);
and abnormal perception/thought content (NPI: delu-
sions and hallucinations).
In accordance with this recommendation, a first
scale to measure MBI symptoms has recently been
published [33]. The standardization of the assessment
of MBI will help to define a target population for
new treatment research or potential greater efficacy
of older treatments.
In the present study, and as far as we know for the
first time in the dementia knowledge field, research
was conducted to analyze MBI and MCI patients as
well as a psychiatric group (PG) in order to compare
their risk of progression to dementia. We followed up
348 patients for a period of five years: 183 suspected
of pre-dementia (MCI and MBI) and 165 patients
with recognized general psychiatric disorders.
Among considered co-morbidities, significant dif-
ferences were found between groups. This finding
might have importance as there are studies suggest-
ing that, in higher income countries, the incidence of
dementia has decreased due to prevention strategies
and social changes such as improvement in edu-
cation and better control of modifiable risk factors
[34–36].
Concerning family background, the MBI group
was the one who had the highest family history of
dementia. Our hypothesis is that MBI patients tend to
convert more frequently to FTD and, therefore, they
could have more significant family background. On a
genetic basis, this could be explained by the fact that
approximately 1 to 5% of Alzheimer’s disease (AD)
patients could be a consequence of dominant auto-
somal mutations [37] and, although most cases of
FTD are sporadic, 20% to 40% have been described
as relatives, most of them presenting an autosomal
dominant pattern [38, 39].
Differences found in the neurological exam
between groups demonstrate that the MBI group had
more neurological signs (pyramidal signs, extrapyra-
midal signs, and archaic reflexes). Extrapyramidal
signs could be explained by pharmacological adverse
events, since this group, as it is depicted in Table 2,
is the one who significantly used more psychophar-
macological medication. Moreover, and regarding all
neurological signs, the MBI group presented signifi-
cant global functional abnormalities and frontal lobe
abnormalities in SPECT and PET neuroimages when
compared to the other groups. However, there were
no significant differences between the MCI and MBI
groups with underling vascular disease, and anatom-
ical neuroimaging findings (MRI and CT scan). This
matter is not further developed as it is beyond the
scope of this paper.
Regarding NPS symptoms, we found that irri-
tability, disinhibition, and delusions followed by
depression and apathy were the predominant symp-
toms in the MBI group, while anxiety and irritability
were the most frequent in MCI group.
There are many research studies describing
behavioral symptoms of mild type (mostly depres-
sive) associated with MCI [2, 3, 40–43]. The
results observed in Beck Depression Inventory
in both groups (MCI, MBI) could be related to
the fact that this self-administered questionnaire
emphasizes more of the cognitive component of
depression (decision making, work performance,
fatigue/slowing down), since the symptoms of this
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Mortby et al. in a recent publication observed that
a number of co-morbid NPS in MCI patients and not
symptom clusters were associated with increased risk
of dementia [44]. These findings highlight the impor-
tance of NPS and the need for clinicians to consider
the presence of NPS in cognitively normal subjects
as a possible risk state.
According to the five subcategories described
by the ISTAART about behavioral changes, the
symptoms we registered in the MBI group could
be related to the following subcategories: affective
dysregulation (irritability and depression), impulse
control (disinhibition), abnormal perception/thought
content (delusions), and decreased motivation (apa-
thy). In the MCI group, observed symptoms
(anxiety and irritability) could be classified as
affective dysregulation according to the ISTAART
criteria.
Although the MBI group included patients
with ‘no complaint of cognitive impairment’ by
patient/informant, the MBI group had worst cognitive
performance in some cognitive domains than the MCI
group (for example in MMSE). This might reflect that
MBI patients have no awareness and/or perception of
their cognitive impairments.
Concerning cognitive symptoms in MCI and MBI
groups, MCI is worse on memory impairment while
MBI patients with cognitive symptoms performed
worse on language domain [Boston Naming Test
(p = 0.024) and executive domain (Trail Making B
test)].
With regards to the worst performance of MBI
patients in the language domain (Boston naming test),
one of our hypothesis is that as MBI patients tend
to convert in a higher proportion to FTD, some of
the cases of FTD could correspond to language vari-
ants such as semantic primary progressive aphasia
(svPPA). As a recent research study demonstrated that
both at baseline and follow-up, svPPA patients exhib-
ited significantly more behavioral disturbances of the
type characteristic of behavioral FTD compared with
other PPA variants [45].
Moreover, we conducted a research study in PPA
patients in 2010 where we observed that patients with
PPA may suffer behavioral alterations like apathy,
anxiety, and depression, and we wondered if these
symptoms could be part of diagnostic criteria of this
disorder [46].
Our second hypothesis is that this impairment in
language tests in MBI patients could correspond to
atypical presentations of AD. Cases of PPA, like
semantic dementia with the initial complaint of for-
getfulness can be diagnosed as AD [47]. Agrammatic,
logopenic, and semantic subtypes, each reflecting a
characteristic pattern of language impairment and
corresponding anatomical distribution of cortical
atrophy, represent the most frequent presentations
of PPA. The underlying neuropathology of PPA is,
most commonly, frontotemporal lobar degeneration
in the agrammatic and semantic forms, while in
AD, the logopenic form is the most frequent. AD
pathology often displays atypical and asymmetri-
cal anatomical features consistent with the aphasic
phenotype [48].
Concerning MBI, worst performance in executive
functions; as Cummings and colleagues demon-
strated (2004), a high percentage of patients (64%)
with AD presented with executive dysfunctional dis-
order. These performed worse on tests of cognition,
dementia severity, and activities of daily living. They
also had more frequent symptoms of psychosis at
baseline compared with patients with normal exec-
utive function [49].
From our total patients, 36.2% converted to demen-
tia. Conversion was significantly higher in MBI
71.5% followed by the MCI-MBI overlap group
(59.6%) and MCI (37.8%) group, compared to PG
13.9% (Log-rank p < 0.001).
Our hypothesis for these findings is that patients
with NPS symptoms, as early manifestations of neu-
rodegenerative diseases, tend to consult later in the
course of the disease. A possible explanation for
this idea is that people are generally more concerned
about memory problems than in behavioral changes
which are usually ignored by the patients or the family
members.
From an integrative point of view, the incorpo-
ration of neuropsychiatric markers to primary care
health may facilitate a synergistic development of
preventive interventions. The adoption of the MBI
concept along with MCI by the general physician
community could lead to an advance in the knowledge
of the pre-dementia diagnosis.
Another finding of this research study was that
the vast majority of MCI patients tend to convert to
Alzheimer’s dementia while MBI patients evolve to
a wider range of neurodegenerative diseases, prin-
cipally FTD, followed by LBD and Alzheimer’s
dementia. Instead, patients in the PG evolve to LBD
and FTD. Moreover, we observed that all cases of
LBD were preceded by NPS (no patients evolved
from MCI to LBD).
The strength of our study is the inclusion of the PG
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stages of neurodegenerative diseases. The conver-
sion rate to dementia was significantly lower in PG
patients (13.9%, p < 0.001) although they present
other psychiatric disorders that could predispose to
functional impairment or loss of independence. Dif-
ferentiation between MBI in two subgroups (MBI
with and without CogS) and their rate of conversion
to dementia is a novel finding.
Our study has several limitations. One of them
is that our results are based on a selected group of
patients referred for consultation to a dementia unit
(Neuropsychiatry Research Unit, CEMIC University
Hospital). Another one is that there might be over-
lap between the MCI with-NPS group described in
this research and the MBI with-cognitive impairment
group, described in our previous study [13]. There-
fore, the “no cognitive complaints criterion” of the
MBI diagnosis should be improved in future investi-
gations to better differentiate these groups.
Another limitation to consider is the variability of
diagnosis on behavioral impairments due to the dif-
ferent cultural influences. In this way, the report of
behavioral symptoms could vary from one population
to another but, since our research has been carried out
with a homogeneous population, the study maintains
cohesion and internal validity.
To conclude, the MBI concept is an advance in the
diagnosis of pre-dementia populations and its iden-
tification should help in prevention and therapeutic
interventions.
This study provides useful data for the diagnosis
and management of pre-dementia stages with pos-
sible applications for primary care practitioners and
other care and social providers in the general popu-
lation.
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